5th International Conference on Neuroscience and Mental Health

Psychedelic-assisted therapy is experiencing one of the most remarkable scientific renaissances in the history of neuroscience and psychiatry. After decades of prohibition and neglect, compounds such as psilocybin, MDMA, ketamine, LMD, and DMT are now the subject of rigorous, high-quality clinical research, and the results are extraordinary. Multiple Phase 2 and Phase 3 clinical trials have demonstrated compelling evidence for the efficacy of these substances in treating some of the most difficult-to-treat conditions in psychiatry, including treatment-resistant depression, PTSD, alcohol use disorder, and end-of-life anxiety.

The neuroscientific mechanisms underlying psychedelic effects are as fascinating as they are clinically relevant, and this session will offer a deep exploration of how these compounds act on the brain. From psilocybin's effects on serotonin 5-HT2A receptors and default mode network activity, to MDMA's unique ability to promote fear extinction and therapeutic rapport, to ketamine's rapid antidepressant effects via NMDA receptor modulation, this session will illuminate the diverse pharmacological mechanisms through which psychedelics exert their transformative effects on consciousness, emotion, and cognition. Neuroimaging studies that have captured the brain in altered states will be featured, offering spectacular visual and scientific insights into the psychedelic experience.

The regulatory, ethical, and clinical implementation dimensions of psychedelic-assisted therapy will also be comprehensively addressed. As regulatory agencies around the world begin to consider or approve psychedelic-based medicines, questions of safety, therapist training, informed consent, integration therapy, and equitable access are becoming critically important. This session will bring together clinicians, ethicists, and policy experts to navigate these complex issues, ensuring that the psychedelic therapy revolution develops in a way that is safe, ethical, evidence-based, and accessible to the patients who need it most. This is one of the most anticipated sessions of the conference, not to be missed.

Key Topics:

• Psilocybin for Treatment-Resistant Depression: Phase 2 and Phase 3 clinical trial evidence for psilocybin-assisted therapy in treatment-resistant and major depression.
• MDMA-Assisted Therapy for PTSD: Neurobiology, clinical trial outcomes, and therapeutic protocols for MDMA-assisted psychotherapy in PTSD.
• Ketamine and Esketamine: Mechanisms of action, clinical evidence, and practical use of ketamine and esketamine for treatment-resistant depression.
• Neuroimaging the Psychedelic Brain: What fMRI, MEG, and EEG studies reveal about altered states of consciousness, default mode network disruption, and psychedelic mechanisms.
• Serotonin Receptor Pharmacology: How psychedelics act on 5-HT2A and other serotonin receptors, and the implications for understanding psychiatric treatment.
• Therapeutic Protocols and Integration: Design of psychedelic therapy sessions, the role of the therapeutic relationship, and the importance of integration therapy.
• Safety and Ethics: Adverse event management, screening and contraindications, ethical considerations, and regulatory frameworks for psychedelic therapy.
• Microdosing and Novel Compounds: Emerging research on microdosing, non-hallucinogenic analogues, and next-generation psychedelic compounds in development.